Intravesical injections of botulinum toxin type a for management of neuropathic bladder: A comparison of two methods

Saeed Safari, Sara Jamali, Peiman Habibollahi, Hamid Arshadi, Farideh Nejat, Abdol Mohammad Kajbafzadeh

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVES To evaluate and compare the efficacy of botulinum toxin intravesical injections with and without injections in external urethral sphincter in treating bladder hyper-reflexia in children suffering from myelomeningocele. METHODS A total of 60 patients with bladder hyper-reflexia due to myelomeningocele were randomly allocated to treatment groups A and B and were followed up for 6 months. Under cystoscopic guidance, 10 IU/kg of botulinum toxin A was injected into the detrusor muscle, sparing the trigone and ureteral orifices in group A. Group B received 8 IU/kg of toxin via the same method compared with group A and 2 IU/kg of toxin through 4 injections in external urethral sphincter. Conventional urodynamics, daily incontinence score, constipation, and creatinine level were evaluated at baseline, 3 months, and 6 months after intervention. Vesicoureteral reflux was also assessed before and after 3 months of injections. RESULTS All patients showed significant improvement in bladder capacity (P <.01), maximal detrusor pressure (P <.01), and detrusor-sphincter dyssynergia (P <.01) after 3 and 6 months of receiving injections. Significant improvement in postvoiding residual volume was observed only among patients of group B (P <.05). Both methods resulted in a significant reduction in daily incontinence grade, constipation, and vesicoureteral reflux (P <.05), but comparison between the study groups showed better outcomes for group B in relation to incontinency, constipation, vesicoureteral reflux, and creatinine level. CONCLUSIONS Botulinum toxin type A injections in both sphincter and detrusor seems to have extra benefits such as decreasing postvoiding residual volume and more symptom diminution compared with intradetrusal injections alone. UROLOGY 76: 225-232, 2010.

Original languageEnglish (US)
Pages (from-to)225-230
Number of pages6
JournalUrology
Volume76
Issue number1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Intravesical Administration
Neurogenic Urinary Bladder
Botulinum Toxins
Vesico-Ureteral Reflux
Injections
Constipation
Meningomyelocele
Type A Botulinum Toxins
Urinary Bladder
Residual Volume
Urethra
Creatinine
Urodynamics
Ataxia
Pressure
Muscles

ASJC Scopus subject areas

  • Urology

Cite this

Intravesical injections of botulinum toxin type a for management of neuropathic bladder : A comparison of two methods. / Safari, Saeed; Jamali, Sara; Habibollahi, Peiman; Arshadi, Hamid; Nejat, Farideh; Kajbafzadeh, Abdol Mohammad.

In: Urology, Vol. 76, No. 1, 07.2010, p. 225-230.

Research output: Contribution to journalArticle

Safari, Saeed ; Jamali, Sara ; Habibollahi, Peiman ; Arshadi, Hamid ; Nejat, Farideh ; Kajbafzadeh, Abdol Mohammad. / Intravesical injections of botulinum toxin type a for management of neuropathic bladder : A comparison of two methods. In: Urology. 2010 ; Vol. 76, No. 1. pp. 225-230.
@article{30a44e3e6a994d0a9dd24b2f2b4271f5,
title = "Intravesical injections of botulinum toxin type a for management of neuropathic bladder: A comparison of two methods",
abstract = "OBJECTIVES To evaluate and compare the efficacy of botulinum toxin intravesical injections with and without injections in external urethral sphincter in treating bladder hyper-reflexia in children suffering from myelomeningocele. METHODS A total of 60 patients with bladder hyper-reflexia due to myelomeningocele were randomly allocated to treatment groups A and B and were followed up for 6 months. Under cystoscopic guidance, 10 IU/kg of botulinum toxin A was injected into the detrusor muscle, sparing the trigone and ureteral orifices in group A. Group B received 8 IU/kg of toxin via the same method compared with group A and 2 IU/kg of toxin through 4 injections in external urethral sphincter. Conventional urodynamics, daily incontinence score, constipation, and creatinine level were evaluated at baseline, 3 months, and 6 months after intervention. Vesicoureteral reflux was also assessed before and after 3 months of injections. RESULTS All patients showed significant improvement in bladder capacity (P <.01), maximal detrusor pressure (P <.01), and detrusor-sphincter dyssynergia (P <.01) after 3 and 6 months of receiving injections. Significant improvement in postvoiding residual volume was observed only among patients of group B (P <.05). Both methods resulted in a significant reduction in daily incontinence grade, constipation, and vesicoureteral reflux (P <.05), but comparison between the study groups showed better outcomes for group B in relation to incontinency, constipation, vesicoureteral reflux, and creatinine level. CONCLUSIONS Botulinum toxin type A injections in both sphincter and detrusor seems to have extra benefits such as decreasing postvoiding residual volume and more symptom diminution compared with intradetrusal injections alone. UROLOGY 76: 225-232, 2010.",
author = "Saeed Safari and Sara Jamali and Peiman Habibollahi and Hamid Arshadi and Farideh Nejat and Kajbafzadeh, {Abdol Mohammad}",
year = "2010",
month = "7",
doi = "10.1016/j.urology.2009.09.087",
language = "English (US)",
volume = "76",
pages = "225--230",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Intravesical injections of botulinum toxin type a for management of neuropathic bladder

T2 - A comparison of two methods

AU - Safari, Saeed

AU - Jamali, Sara

AU - Habibollahi, Peiman

AU - Arshadi, Hamid

AU - Nejat, Farideh

AU - Kajbafzadeh, Abdol Mohammad

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVES To evaluate and compare the efficacy of botulinum toxin intravesical injections with and without injections in external urethral sphincter in treating bladder hyper-reflexia in children suffering from myelomeningocele. METHODS A total of 60 patients with bladder hyper-reflexia due to myelomeningocele were randomly allocated to treatment groups A and B and were followed up for 6 months. Under cystoscopic guidance, 10 IU/kg of botulinum toxin A was injected into the detrusor muscle, sparing the trigone and ureteral orifices in group A. Group B received 8 IU/kg of toxin via the same method compared with group A and 2 IU/kg of toxin through 4 injections in external urethral sphincter. Conventional urodynamics, daily incontinence score, constipation, and creatinine level were evaluated at baseline, 3 months, and 6 months after intervention. Vesicoureteral reflux was also assessed before and after 3 months of injections. RESULTS All patients showed significant improvement in bladder capacity (P <.01), maximal detrusor pressure (P <.01), and detrusor-sphincter dyssynergia (P <.01) after 3 and 6 months of receiving injections. Significant improvement in postvoiding residual volume was observed only among patients of group B (P <.05). Both methods resulted in a significant reduction in daily incontinence grade, constipation, and vesicoureteral reflux (P <.05), but comparison between the study groups showed better outcomes for group B in relation to incontinency, constipation, vesicoureteral reflux, and creatinine level. CONCLUSIONS Botulinum toxin type A injections in both sphincter and detrusor seems to have extra benefits such as decreasing postvoiding residual volume and more symptom diminution compared with intradetrusal injections alone. UROLOGY 76: 225-232, 2010.

AB - OBJECTIVES To evaluate and compare the efficacy of botulinum toxin intravesical injections with and without injections in external urethral sphincter in treating bladder hyper-reflexia in children suffering from myelomeningocele. METHODS A total of 60 patients with bladder hyper-reflexia due to myelomeningocele were randomly allocated to treatment groups A and B and were followed up for 6 months. Under cystoscopic guidance, 10 IU/kg of botulinum toxin A was injected into the detrusor muscle, sparing the trigone and ureteral orifices in group A. Group B received 8 IU/kg of toxin via the same method compared with group A and 2 IU/kg of toxin through 4 injections in external urethral sphincter. Conventional urodynamics, daily incontinence score, constipation, and creatinine level were evaluated at baseline, 3 months, and 6 months after intervention. Vesicoureteral reflux was also assessed before and after 3 months of injections. RESULTS All patients showed significant improvement in bladder capacity (P <.01), maximal detrusor pressure (P <.01), and detrusor-sphincter dyssynergia (P <.01) after 3 and 6 months of receiving injections. Significant improvement in postvoiding residual volume was observed only among patients of group B (P <.05). Both methods resulted in a significant reduction in daily incontinence grade, constipation, and vesicoureteral reflux (P <.05), but comparison between the study groups showed better outcomes for group B in relation to incontinency, constipation, vesicoureteral reflux, and creatinine level. CONCLUSIONS Botulinum toxin type A injections in both sphincter and detrusor seems to have extra benefits such as decreasing postvoiding residual volume and more symptom diminution compared with intradetrusal injections alone. UROLOGY 76: 225-232, 2010.

UR - http://www.scopus.com/inward/record.url?scp=77955899213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955899213&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2009.09.087

DO - 10.1016/j.urology.2009.09.087

M3 - Article

C2 - 20110117

AN - SCOPUS:77955899213

VL - 76

SP - 225

EP - 230

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -